Search Results for: prostate cancer

Men age 75 and older should not be screened for prostate cancer, and younger men should discuss the benefits and harms of the prostate-specific antigen test with their clinicians before being tested, according to a new recommendation from the U.S. Preventive Services Task Force.

Aureon Laboratories Inc, Yonkers, NY, has introduced Prostate Px+, a commercial test that predicts prostate cancer progression and disease recurrence at the time of diagnosis.

Immunicon Corp, Huntingdon Valley, Pa, has been granted FDA has clearance for the CellSearch circulating tumor cell kit as an aid in the monitoring of patients with metastatic prostate cancer.

Iris Molecular Diagnostics, a subsidiary of Iris International Inc, has filed a 510(k) application with the FDA for its ultra-sensitive Prostate-Specific Antigen (PSA) test.